TY - JOUR T1 - A Multiplexed, Next Generation Sequencing Platform for High-Throughput Detection of SARS-CoV-2 JF - medRxiv DO - 10.1101/2020.10.15.20212712 SP - 2020.10.15.20212712 AU - Marie-Ming Aynaud AU - J. Javier Hernandez AU - Seda Barutcu AU - Ulrich Braunschweig AU - Kin Chan AU - Joel D. Pearson AU - Daniel Trcka AU - Suzanna L. Prosser AU - Jaeyoun Kim AU - Miriam Barrios-Rodiles AU - Mark Jen AU - Siyuan Song AU - Jess Shen AU - Christine Bruce AU - Bryn Hazlett AU - Susan Poutanen AU - Liliana Attisano AU - Rod Bremner AU - Benjamin J. Blencowe AU - Tony Mazzulli AU - Hong Han AU - Laurence Pelletier AU - Jeffrey L. Wrana Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/20/2020.10.15.20212712.abstract N2 - Population scale sweeps of viral pathogens, such as SARS-CoV-2, that incorporate large numbers of asymptomatic or mild symptom patients present unique challenges for public health agencies trying to manage both travel and local spread. Physical distancing is the current major strategy to suppress spread of the disease, but with enormous socio-economic costs. However, modelling and studies in isolated jurisdictions suggest that active population surveillance through systematic molecular diagnostics, combined with contact tracing and focused quarantining can significantly suppress disease spread1-3 and has significantly impacted disease transmission rates, the number of infected people, and prevented saturation of the healthcare system4-7. However, reliable systems allowing for parallel testing of 10-100,000’s of patients in larger urban environments have not yet been employed. Here we describe “COVID-19 screening using Systematic Parallel Analysis of RNA coupled to Sequencing” (C19-SPAR-Seq), a scalable, multiplexed, readily automated next generation sequencing (NGS) platform8 that is capable of analyzing tens of thousands of COVID-19 patient samples in a single instrument run. To address the strict requirements in clinical diagnostics for control of assay parameters and output, we employed a control-based Precision-Recall and predictive Receiver Operator Characteristics (coPR) analysis to assign run-specific quality control metrics. C19-SPAR-Seq coupled to coPR on a trial cohort of over 600 patients performed with a specificity of 100% and sensitivity of 91% on samples with low viral loads and a sensitivity of > 95% on high viral loads associated with disease onset and peak transmissibility. Our study thus establishes the feasibility of employing C19-SPAR-Seq for the large-scale monitoring of SARS-CoV-2 and other pathogens.Competing Interest StatementJ. Wrana is founder and CEO of iTP Biomedica Inc, which employs whole transcriptome NGS tests in cancer, and he is founder and consultant for Fibrocor LP, which is developing therapeutics for fibrotic disease. The other authors declare no competing interests.Funding StatementThis work is supported by the Toronto COVID-19 Action Initiative (TCAI) Fund from the University of Toronto awarded to J.L.W, L.P. and R.B., and by a donation from the Krembil Foundation (SHSF Krembil SARS-COV-2) to J.L.W, L.P. and R.B.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Mount Sinai Hospital Research Ethics Board (Study #20-0078-E)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data-sets and corresponding FASTQ files were submitted to GEO (accession number pending). ER -